<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05627700</url>
  </required_header>
  <id_info>
    <org_study_id>CP100962</org_study_id>
    <nct_id>NCT05627700</nct_id>
  </id_info>
  <brief_title>AVL200 IOL for Treatment of Cataract and Presbyopia</brief_title>
  <official_title>A Prospective, Open-label, Single-center Study of the Atia™ AVL200 Modular Intraocular Lens System for Treatment of Cataract and Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atia Vision</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atia Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the performance of the AVL200 IOL in terms of visual function&#xD;
      improvement over a range of focal points. Participants meeting eligibility criteria will&#xD;
      undergo cataract surgery with implantation of the AVL200 intraocular lens (IOL), then be&#xD;
      followed through 1 year postoperatively. Postoperative assessments include safety and visual&#xD;
      function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2022</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in monocular best corrected distance visual acuity</measure>
    <time_frame>Baseline, 3 months postoperative</time_frame>
    <description>Best-corrected distance visual acuity as measured using an early-treatment diabetic retinopathy study (ETDRS) eye chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in monocular distance-corrected near visual acuity</measure>
    <time_frame>Baseline, 3 months postoperative</time_frame>
    <description>Distance-corrected distance visual acuity as measured using an early-treatment diabetic retinopathy study (ETDRS) eye chart</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>AVL200 IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The AVL200 is a modular fluid-filled, shape-changing intraocular lens (IOL) designed to restore visual function across a range of focal points</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVL200 IOL</intervention_name>
    <description>The AVL200 is an intraocular lens surgically implanted in the eye after cataract surgery.</description>
    <arm_group_label>AVL200 IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Visually significant cataract&#xD;
&#xD;
          -  Best corrected distance visual acuity between 20/40 and 20/200&#xD;
&#xD;
          -  Potential distance visual acuity of 20/32 or better&#xD;
&#xD;
          -  Corneal astigmatism ≤ 1.5 diopters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of medication that could affect accommodation&#xD;
&#xD;
          -  Previous corneal surgery or significant corneal abnormalities&#xD;
&#xD;
          -  Ocular pathology or degenerative disorder having potential to impair visual acuity&#xD;
&#xD;
          -  Pupil abnormality&#xD;
&#xD;
          -  Intraoperative cataract surgery complications that could affect IOL implantation or&#xD;
             positioning&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashvin Agarwal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Agarwals Eye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Guerrero</last_name>
    <phone>408-560-3339</phone>
    <email>melissa@atiavision.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Preethi Thiagarajan, MD</last_name>
    <email>preethi@atiavision.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr Agarwal's Eye Hospital</name>
      <address>
        <city>Chennai</city>
        <state>Tamal Nadu</state>
        <zip>600018</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>044 4300 8800</phone>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 16, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2022</study_first_posted>
  <last_update_submitted>November 16, 2022</last_update_submitted>
  <last_update_submitted_qc>November 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

